# US 10,478,508 B2 · Compositions, methods and uses for alpha-1 antitrypsin fusion molecules > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,478,508 B2 - Document ID: US10478508B2 - Status: Granted - Kind: B2 - Application number: 14/370,442 - Filed: 2013-01-10 - Published: 2014-11-27 - Granted: 2019-11-19 - Earliest claimed: 2012-01-10 - Assignees: The Regents of the University of Colorado, a body corporate; Konkuk University Industry Cooperation Foundation - Applicants: The Regents of the University of Colorado, a body corporate; Konkuk University Industry Cooperation Foundation - Inventors: Soohyun Kim; Charles A. Dinarello - Web page: https://patentgrep.com/patent/US10478508B2 ## CPC - A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)} - A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin} - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 31/10: Antimycotics - A61P 31/12: Antivirals - A61P 33/00: Antiparasitic agents - A61P 35/00: Antineoplastic agents - A61P 35/02: specific for leukemia - A61P 37/02: Immunomodulators - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07K 14/81: Protease inhibitors - C07K 14/8125: {Alpha-1-antitrypsin} - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract Embodiments herein report compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment. ## Claims ### Claim 1 A nucleic acid construct encoding a fusion polypeptide represented by SEQ ID NO: 49, SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO: 58. ### Claim 2 A nucleic acid construct encoding the fusion polypeptide represented by SEQ ID NO: 49. ### Claim 3 A composition comprising a fusion polypeptide represented by SEQ ID NO: 49, SEQ ID NO: 56, SEQ ID NO: 57 or SEQ ID NO: 58 and a pharmaceutically acceptable carrier. ### Claim 4 (depends on 1) A vector comprising the nucleic acid construct of claim 1. ### Claim 5 An isolated preparation of inclusion bodies comprising a fusion polypeptide represented by SEQ ID NO: 49, SEQ ID NO: 56, SEQ ID NO: 57 or SEQ ID NO: 58. ### Claim 6 A nucleic acid construct encoding a fusion polypeptide represented by SEQ ID NO:56. ### Claim 7 (depends on 3) The composition of claim 3, wherein the fusion polypeptide is represented by SEQ ID NO: 49. ### Claim 8 (depends on 2) A vector comprising the nucleic acid construct of claim 2. ### Claim 9 (depends on 5) The isolated preparation of inclusion bodies of claim 5, wherein the fusion polypeptide is represented by SEQ ID NO: 49. ### Claim 10 (depends on 3) The composition of claim 3, wherein the fusion polypeptide is represented by SEQ ID NO: 56. ### Claim 11 (depends on 6) A vector comprising the nucleic acid construct of claim 6. ### Claim 12 (depends on 5) The isolated preparation of inclusion bodies of claim 5, wherein the fusion polypeptide is represented by SEQ ID NO: 56. ### Claim 13 A nucleic acid construct encoding the fusion polypeptide represented by SEQ ID NO: 57. ### Claim 14 (depends on 3) The composition of claim 3, wherein the fusion polypeptide is represented by SEQ ID NO: 57. ### Claim 15 (depends on 13) A vector comprising the nucleic acid construct of claim 13. ### Claim 16 (depends on 5) The isolated preparation of inclusion bodies of claim 5, wherein the fusion polypeptide is represented by SEQ ID NO: 57. ### Claim 17 A nucleic acid construct encoding a fusion polypeptide represented by SEQ ID NO: 58. ### Claim 18 (depends on 3) The composition of claim 3, wherein the fusion polypeptide is represented by SEQ ID NO: 58. ### Claim 19 (depends on 17) A vector comprising the nucleic acid construct of claim 17. ### Claim 20 (depends on 5) The isolated preparation of inclusion bodies of claim 5, wherein the fusion polypeptide is represented by SEQ ID NO: 58.